Price:
Rs. 199,000.00
Sample Type: Tissue
Fasting Not Required
Notes:N8218
Frequently Asked Questions (FAQ's):
What does the MammaPrint + BluePrint test at Metropolis Healthcare include?
It evaluates genomic risk of recurrence (MammaPrint) and identifies the tumor’s molecular subtype (BluePrint).
How does Metropolis Healthcare perform the MammaPrint + BluePrint analysis?
Metropolis Healthcare uses validated gene-expression technology to assess tumor biology from tissue samples.
Who should consider this test at Metropolis Healthcare?
Patients with early-stage, hormone receptor–positive or negative breast cancer seeking personalized treatment guidance should consider it.
Is fasting required for the MammaPrint + BluePrint test at Metropolis Healthcare?
No fasting is needed; the test uses preserved tumor tissue provided by the clinician.
How long do results take at Metropolis Healthcare?
Results usually take 2–3 weeks due to detailed genomic expression analysis.
Can this test at Metropolis Healthcare help decide if chemotherapy is needed?
Yes, MammaPrint provides a genomic risk score that helps determine the benefit of adding chemotherapy.
How accurate is the genomic profiling done by Metropolis Healthcare?
Metropolis Healthcare follows stringent quality standards to ensure reliable and clinically validated results.
Does this test support long-term treatment planning at Metropolis Healthcare?
Yes, combining risk assessment and molecular subtyping helps clinicians design personalized, long-term management strategies.